Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
Type 2 DiabetesCroatia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
This study is looking at a new treatment called glofitamab for multiple sclerosis (MS). Researchers want to see if it's safe, how well the body handles it, and how it works after patients have taken another medicine called ocrelizumab.
Multiple Sclerosis (MS)Croatia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma
This study is testing a new medicine, Atuliflapon, for adults whose moderate-to-severe asthma isn't well controlled by their usual treatments. We want to see if it reduces asthma flare-ups and improves breathing, compared to a dummy pill, over 12 weeks.
Moderate-to-Severe Uncontrolled AsthmaCroatia - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaCroatia - Active not recruitingPHASE3
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
This study is looking at a new medicine called Dazodalibep for people with Sjögren's Syndrome. It aims to see how well it helps with symptoms and whether it's safe to use, especially for those with moderate to severe symptoms.
Sjögren's Syndrome (SS)Croatia - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisCroatia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
This study is looking for new ways to help adults with severe asthma that isn't well controlled. It tests a new drug, GB-0895, alongside their usual asthma medicine, to see if it reduces severe asthma attacks.
severe uncontrolled asthmaCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Croatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Croatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
This study is looking at a new medicine, sotatercept, for people recently diagnosed with a serious lung condition called Pulmonary Arterial Hypertension (PAH). It compares sotatercept to a dummy medicine to see if it improves well-being and reduces serious health events when added to standard treatments.
Therapeutic confirmatory (phase III)Croatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
Focal segmental glomerulosclerosis (FSGS)Croatia - Active not recruitingNA
REDUCE LAP-HF TRIAL II
This study looks at a new tiny device, the IASD System II, for people with heart failure. It aims to see if this implant can improve symptoms and quality of life by helping the heart manage pressure better. Half the people get the implant, and half get a check-up without it.
Heart FailureCroatia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension
This study is testing a new medicine, BHV-7000, for people aged 18 and over who have a type of epilepsy called idiopathic generalised epilepsy with tonic-clonic seizures. Doctors want to see if the medicine can reduce these seizures and if it's safe to use.
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic SeizuresCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
This study is looking at the long-term safety of a medicine called Avacincaptad pegol for people with a serious eye condition called geographic atrophy. It's for those who have already been in a previous study using this medicine.
geographic atrophyCroatia - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisCroatia - Enrolling by invitationPHASE2, PHASE3
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
This study looks at the long-term safety and effects of a medicine called sibeprenlimab for people with a kidney condition called IgA Nephropathy. It's for those who have already been part of earlier studies with this medicine.
Immunoglobulin A NephropathyCroatia - Ongoing, recruitingPhase III and phase IV (Integrated)
Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia – LEASH
This study looks at how well different medications (Sorvasta and Sorvitimb) lower 'bad' cholesterol (LDL-C) in people who have high cholesterol and are at high risk of heart problems. It checks if patients reach their target cholesterol levels after 12 weeks.
HyperlipidaemiaCroatia - AuthorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
This study is looking at a new version of a medication for schizophrenia. It compares how this new version is handled by the body to an existing medication, to see if they work in a similar way after several doses.
SchizophreniaCroatia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Croatia - Not yet recruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisCroatia - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerCroatia - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisCroatia - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisCroatia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesCroatia - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisCroatia - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsCroatia - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionCroatia - Active not recruitingPHASE3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.
Hidradenitis SuppurativaCroatia - AuthorisedTherapeutic use (Phase IV)
A Randomized Trial of the I-BFM-SG for the Management of Childhood non-mature-B Acute Lymphoblastic Leukemia
This study is looking at new treatments for a type of childhood leukaemia. It aims to see if adding Riximyo to standard chemotherapy helps children live longer without the leukaemia coming back. The study also checks for side effects.
Childhood non-mature-B Acute Lymphoblastic LeukemiaCroatia - RecruitingPHASE3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This study is looking into a new medication called KarXT for people with memory problems like Alzheimer's who also experience psychosis. It compares KarXT to a dummy pill to see if it can prevent these symptoms from returning and if it's safe to use.
Psychosis Associated With Alzheimer's DiseaseCroatia - RecruitingPHASE3
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
This study looks at the long-term safety of a medicine called vedolizumab for children and young people with Crohn's disease or ulcerative colitis. It's for those who have already taken part in a previous study with vedolizumab.
Ulcerative ColitisCrohn's DiseaseCroatia - RecruitingPHASE3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
This study looks at a new medicine called felzartamab for adults with a kidney disease called IgA nephropathy (IgAN). Researchers want to see if it reduces protein in the urine and helps kidney function. It involves infusions and careful monitoring.
Immunoglobulin A Nephropathy (IgAN)Croatia - AuthorisedTherapeutic exploratory (Phase II)
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis
This study looks at a new medicine called balinatunfib for adults with Crohn's disease or ulcerative colitis. It mainly checks for any side effects and how safe it is over a longer time. It also looks at if the treatment helps improve symptoms and gut health.
Crohn's disease, Colitis UlcerativeCroatia - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine called Afimkibart for people with moderate to severe ulcerative colitis. It aims to see how well it works and if it's safe compared to a dummy drug. The study is for adults aged 16 to 80 who haven't found existing treatments helpful.
Moderately to Severely Active Ulcerative ColitisCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
This study looks at a medicine called Entyvio for children and teenagers with moderate to severe ulcerative colitis. It aims to see if Entyvio helps them stay in remission (when symptoms improve or disappear) and if it's safe to use over time.
Moderately to severely active Ulcerative Colitis (UC)Croatia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerCroatia - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseCroatia - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
This study is testing a new medicine called efgartigimod for adults with a blood condition called primary immune thrombocytopenia (ITP). Researchers want to see if it's safe and helps increase blood platelet counts. Some people will get the study drug, others a placebo (dummy drug).
Primary Immune Thrombocytopenia (ITP)Croatia - RecruitingPHASE3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This study is testing a new medicine, XEN1101, alongside usual treatments for a specific type of epilepsy seizure called Primary Generalized Tonic-Clonic Seizures (PGTCS). It aims to see if the new medicine helps reduce these seizures and if it's safe for people aged 12 and older.
Primary Generalized Tonic-Clonic SeizuresCroatia - Enrolling by invitationPHASE3
An Open-label Study of XEN1101 in Epilepsy
This study looks at a medicine called XEN1101 for people with certain types of epilepsy, including focal epilepsy and tonic-clonic seizures. It focuses on how safe and effective it is over a long time, up to six years, after they've been in a previous study.
Focal EpilepsyTonic-Clonic SeizuresCroatia - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungCroatia - RecruitingPHASE3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
This study is looking into the long-term safety of a new medicine called dazodalibep for people with Sjögren's Syndrome. It involves individuals who have already taken part in previous studies of this medicine.
Sjögren's SyndromeCroatia - AuthorisedPhase III and phase IV (Integrated)
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
This study is looking into new ways to help children and teenagers manage their weight. It's testing a medicine called cagrilintide, both by itself and with another medicine called semaglutide, to see how well they work and if they are safe for weight loss.
Obesity and T2DCroatia - Recruiting
European and North Indian Cohort of KaWasaki dIsease
This study looks at Kawasaki disease in children across Europe and North India. Researchers want to better predict which children might not respond to standard treatment, aiming to improve how we care for their hearts and prevent serious heart problems later on.
Kawasaki DiseaseCroatia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.
This study looks at a medicine called Octaplex for people taking blood thinners (DOACs) who have serious bleeding. It checks if Octaplex helps stop the bleeding and if it's safe. Octaplex is a powder mixed into a liquid for a drip.
Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitorCroatia - Recruiting
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
This study, called EFESO, is looking into a rare condition called Eosinophilic Fasciitis in children. We want to understand it better, improve how we diagnose it, and see which treatments work best for young people. It's about helping kids with this condition live healthier lives.
Eosinophilic FasciitisCroatia - Ongoing, recruitingPhase II and Phase III (Integrated)
C5041006 (APD334 202 or APD334-202EU): A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
This study is testing a new medicine called etrasimod for people with moderate to severe Crohn's disease. Researchers want to see if it helps improve symptoms and gut health, and if it is safe to use.
Crohn's DiseaseCroatia - RecruitingPHASE3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
This study looks at how safe and effective a medicine called mezagitamab is for adults with a bleeding condition called ITP. If you’ve been in a previous mezagitamab study, you might be invited to join this longer follow-up.
Immune Thrombocytopenic Purpura (ITP)Croatia - Active not recruitingPHASE2
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
The MoonStone study is looking at a new medicine called obexelimab for people with relapsing multiple sclerosis (MS). It aims to see if obexelimab can help and if it's safe. Participants will get either the new medicine or a dummy treatment, then everyone will get the new medicine.
Relapsing Multiple SclerosisCroatia - Active not recruitingPHASE3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
This study is looking at a new medicine called milvexian to see if it can help prevent another stroke in people who have recently had a mini-stroke or a type of stroke called an ischemic stroke.
Ischemic Stroke; Ischemic Attack, TransientCroatia